As a global, senior healthcare executive, advisor, and Real World Data (RWD) scientist, I enable the growth of biotech, medical device, and health IT companies by fusing 30+ years in research science, big data, analytics, healthcare, clinical, and technology. Leveraging my extensive experience at Astellas, Baxter, AmerisourceBergen, Hospira (Pfizer), and Spectrum-Health, I guide companies across the healthcare continuum in discovering hidden opportunities for value creation and market differentiation by gauging patient needs, provider delivery, and unmet market needs.Currently, as the Managing Director of MedNavigate, I advise emerging to mid-size life sciences companies to design and execute strategies that utilize real-world evidence as a complement to clinical trials and/or other predicate proof points. I am an analytical and strategic advisor who provides valuable insights to advance business goals and articulate unique market positioning, asking astute questions from product design, development, launch, and market fit, to FDA approvals, through payer decisions and reimbursement. Highlights include:• Product Launch – Supporting Lilly (NYSE: LLY) on the pirtobrutinib product launch (Mantle Cell Lymphoma & chronic lymphocytic leukemia (CLL)). Guided product launches in AML, urothelial cancer, & prostate cancer via RWD studies and projects (Astellas).• Health Tech – Led Hospira (Pfizer) in deploying >730 intelligent infusion installations across large, integrated delivery networks (US/Global). Guided Spectrum-Health’s EHR implementation for IV robot compounding system and inventory mgmt. carousels for a multi-hospital health system.• Big Data & Analytics – Advise companies across patients, providers, unmet market needs, products, & payers via large RWD sources (insurance claims, databases, EMR). Stood up/guided Baxter’s RWD team supporting HEOR function for Hospital Products Business. Advised Astellas on RWD assets to support health economics, market access, drug development, and pharmacovigilance for 3 oncology compounds (Xtandi, PACDEV, Xospata).• Rapid Growth – Steered Hospira (Pfizer) Pharmacy consulting program of mid-large IDN clients, facilitating collection of $300M in medical device capital revenue and generating ~ $3M in annual consultant fees.• Portfolio Strategy – Advised AmerisourceBergen on product marketing/mgmt. across a suite of tech products portfolio for IDNs, including automated dispensing cabinets and digital order software.
Listed skills include Healthcare, Medical Devices, Pharmaceutical Industry, Cross Functional Team Leadership, and 22 others.